Document is current

Article History

Accepted: 13 August 2024

First Online: 16 September 2024

Declarations

:

: Consultancy in the development of the framework, and medical writing support were funded by Novartis Pharma AG. Open Access publication of this paper was sponsored by Novartis Pharma AG.

: BK is an employee and shareholder of Novartis Pharma AG. EMP has performed paid advisory roles and consultancy on meaningful patient engagement for Novartis. EMO is employed by Applied Patient Experience, LLC, which has contracts with a variety of nonprofit organizations, pharmaceutical companies, and academic institutions, including paid advisory roles and consultancy on meaningful patient engagement for Novartis. FW is an employee of Avalere Health and participated in this work in an independent capacity. FW has performed paid advisory roles and consultancy on meaningful patient engagement for Novartis. TCAL has performed paid advisory roles and consultancy on meaningful patient engagement for Novartis. MB is an employee and shareholder of Novartis Pharma AG. No authors received financial compensation for their involvement in authoring this manuscript.

: Due to the nature of the research, supporting data are not available.

: Not applicable.

: Not applicable.

: Not applicable (no identifiable information).

: Not applicable.

: All authors were closely involved in the iterative development and critical review of the presented framework. BK also provided direction for the background environment analysis. All authors contributed to the development, revision, and critical review of the manuscript. All authors read and approved the final version. The responsibility for opinions and conclusions presented herein lies with the authors.